表皮生长因子受体酪氨酸激酶抑制剂治疗罕见表皮生长因子受体突变的转移性非小细胞肺癌：播客。
EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast.
机构信息
The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Baylor University Medical Center, Dallas, TX, USA.
出版信息
Target Oncol. 2023 Nov;18(6):807-817. doi: 10.1007/s11523-023-00994-2. Epub 2023 Oct 4.
Abstract
Supplementary file1 (MP4 21169 KB).
摘要
补充文件 1（MP4，21169KB）。
相似文献
1
EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast.表皮生长因子受体酪氨酸激酶抑制剂治疗罕见表皮生长因子受体突变的转移性非小细胞肺癌：播客。
Target Oncol. 2023 Nov;18(6):807-817. doi: 10.1007/s11523-023-00994-2. Epub 2023 Oct 4.
2
Correlation between the qualification for bevacizumab use and the survival of patients with non-small cell lung cancer harboring the epidermal growth factor receptor mutation: a retrospective analysis.贝伐珠单抗使用资格与携带表皮生长因子受体突变的非小细胞肺癌患者生存的相关性：一项回顾性分析。
J Cancer Res Clin Oncol. 2019 Oct;145(10):2555-2564. doi: 10.1007/s00432-019-02985-1. Epub 2019 Jul 26.
3
Afatinib, an effective treatment for patient with lung squamous cell carcinoma harboring uncommon EGFR G719A and R776C co-mutations.阿法替尼是治疗罕见 EGFR G719A 和 R776C 共突变肺鳞癌患者的有效药物。
J Cancer Res Clin Oncol. 2022 May;148(5):1265-1268. doi: 10.1007/s00432-021-03864-4. Epub 2022 Mar 1.
4
Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.局部晚期或转移性非小细胞肺癌成人患者的表皮生长因子受体酪氨酸激酶（EGFR-TK）突变检测：一项系统评价与成本效益分析
Health Technol Assess. 2014 May;18(32):1-166. doi: 10.3310/hta18320.
5
Excellent survival benefit achieved in patients with advanced-stage non-small cell lung cancer harboring the epidermal growth factor receptor-G719X mutation treated by afatinib: the real-world data from a multicenter study in Vietnam.在越南一项多中心研究的真实世界数据中，携带表皮生长因子受体-G719X突变的晚期非小细胞肺癌患者接受阿法替尼治疗可获得卓越的生存获益。
Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251341747. doi: 10.1177/17534666251341747. Epub 2025 May 24.
6
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation.辅助性表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKIs）用于治疗已切除的Ⅰ至Ⅲ期非小细胞肺癌且伴有EGFR突变的患者。
Cochrane Database Syst Rev. 2025 May 27;5(5):CD015140. doi: 10.1002/14651858.CD015140.pub2.
7
Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters.不同类型 EGFR 突变的晚期非小细胞肺癌患者接受一线酪氨酸激酶抑制剂治疗的临床结局：脑转移和新出现的 T790M 很重要。
BMC Cancer. 2022 Feb 21;22(1):198. doi: 10.1186/s12885-022-09245-5.
8
Distinct Role of TP53 Co-mutations in Different EGFR Subtypes Mediating the Response to EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.TP53共突变在不同EGFR亚型中介导非小细胞肺癌对EGFR酪氨酸激酶抑制剂反应中的独特作用
Clin Lung Cancer. 2025 Sep;26(6):478-491.e7. doi: 10.1016/j.cllc.2025.04.007. Epub 2025 Apr 23.
9
Mutational landscape and tyrosine kinase inhibitor sensitivity in EGFR L833 and H835 mutated non-small cell lung cancer.EGFR L833和H835突变的非小细胞肺癌的突变图谱及酪氨酸激酶抑制剂敏感性
Cancer. 2025 Sep 1;131(17):e70063. doi: 10.1002/cncr.70063.
10
A case report of a lung cancer patient with two uncommon EGFR mutations and a review of the literature: two sides of the same coin.肺癌患者两种罕见 EGFR 突变病例报告及文献复习：一枚硬币的两面。
Anticancer Drugs. 2024 Jan 1;35(1):76-80. doi: 10.1097/CAD.0000000000001517. Epub 2023 Mar 10.
引用本文的文献
1
How to select between osimertinib or afatinib in P-loop and αC-helix compressing (G719X, S768I) or classical-like (L861Q) EGFR mutations: what preclinical models and clinical data have taught us in the early 2020s.在P环和αC螺旋压缩型（G719X、S768I）或类经典型（L861Q）表皮生长因子受体（EGFR）突变中如何选择奥希替尼或阿法替尼：21世纪20年代初临床前模型和临床数据带给我们的启示
Transl Cancer Res. 2025 Jan 31;14(1):16-23. doi: 10.21037/tcr-24-1827. Epub 2025 Jan 20.
2
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve -Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial).一项关于奥希替尼联合或不联合雷莫西尤单抗用于酪氨酸激酶抑制剂初治的EGFR突变转移性非小细胞肺癌的多中心开放标签随机II期研究（RAMOSE试验）。
J Clin Oncol. 2025 Feb;43(4):403-411. doi: 10.1200/JCO.24.00533. Epub 2024 Oct 8.
3
A Real-World Study of Patient Characteristics and Clinical Outcomes in Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice.一线奥希替尼治疗突变型肺癌患者特征及临床结局的真实世界研究：将 FLAURA 试验结果扩展至常规临床实践
Cancers (Basel). 2024 Mar 7;16(6):1079. doi: 10.3390/cancers16061079.
本文引用的文献
1
UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN).非常见 EGFR 突变：奥希替尼在一线治疗中真实世界疗效的国际病例系列研究（UNICORN）。
J Thorac Oncol. 2023 Feb;18(2):169-180. doi: 10.1016/j.jtho.2022.10.004. Epub 2022 Oct 25.
2
Osimertinib in non-small cell lung cancer with uncommon -mutations: a subgroup analysis with pooled data from two phase II clinical trials.奥希替尼用于治疗具有罕见突变的非小细胞肺癌：一项对两项II期临床试验汇总数据的亚组分析。
Transl Lung Cancer Res. 2022 Jun;11(6):953-963. doi: 10.21037/tlcr-21-995.
3
Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China.达可替尼用于携带主要罕见表皮生长因子受体（EGFR）改变的晚期非小细胞肺癌患者：一项在中国开展的双中心、单臂、双向队列研究
Front Pharmacol. 2022 Jun 13;13:919652. doi: 10.3389/fphar.2022.919652. eCollection 2022.
4
Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.非小细胞肺癌，2022年第3版，美国国立综合癌症网络（NCCN）肿瘤学临床实践指南
J Natl Compr Canc Netw. 2022 May;20(5):497-530. doi: 10.6004/jnccn.2022.0025.
5
Systemic and Intracranial Efficacy of Osimertinib in L747P-Mutant NSCLC: Case Report.奥希替尼治疗L747P突变型非小细胞肺癌的全身及颅内疗效：病例报告
JTO Clin Res Rep. 2022 Feb 15;3(3):100291. doi: 10.1016/j.jtocrr.2022.100291. eCollection 2022 Mar.
6
The Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors.非小细胞肺癌中罕见表皮生长因子受体（EGFR）p.L747P突变的面纱揭开：分子特征及对酪氨酸激酶抑制剂的靶向敏感性
Front Oncol. 2022 Feb 11;12:843299. doi: 10.3389/fonc.2022.843299. eCollection 2022.
7
Testing Patterns and Detection of Exon 20 Insertions in the United States.美国第20外显子插入的检测模式与发现
JTO Clin Res Rep. 2022 Jan 25;3(3):100285. doi: 10.1016/j.jtocrr.2022.100285. eCollection 2022 Mar.
8
Real-world patterns of biomarker testing and targeted therapy in de novo metastatic non-small cell lung cancer patients in the US oncology network.美国肿瘤网络中初发性转移性非小细胞肺癌患者生物标志物检测和靶向治疗的真实世界模式。
Cancer Treat Res Commun. 2022;31:100522. doi: 10.1016/j.ctarc.2022.100522. Epub 2022 Jan 29.
9
Uncommon Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence.非小细胞肺癌（NSCLC）中罕见的复合突变：现有证据的系统评价。
Curr Oncol. 2022 Jan 9;29(1):255-266. doi: 10.3390/curroncol29010024.
10
Molecular Characteristics of the Uncommon EGFR Exon 21 T854A Mutation and Response to Osimertinib in Patients With Non-Small Cell Lung Cancer.非小细胞肺癌患者中罕见的 EGFR 外显子 21 T854A 突变的分子特征及对奥希替尼的反应。
Clin Lung Cancer. 2022 Jun;23(4):311-319. doi: 10.1016/j.cllc.2021.12.008. Epub 2021 Dec 24.
Zotero 插件